John E. Macor
John E.
≈ 7 min read
John E. Macor. encyclopegia.org, snapshot enwiki-001375923447. /a/john-e-macor
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
John E. Macor is an American medicinal chemist known for his contributions to drug discovery in neuroscience and other therapeutic areas.[1] He is a co-inventor of four drugs approved by the U.S. Food and Drug Administration (FDA): the migraine treatments eletriptan (Relpax), rimegepant (Nurtec ODT), and zavegepant (Zavzpret), and sparsentan (Filspari), a treatment for IgA nephropathy.[2][3][4][5][6]
In 2014, he was inducted into the Hall of Fame of the American Chemical Society’s Division of Medicinal Chemistry.[2]
Macor currently works at Babylon Biosciences, a San Francisco-based startup focused on treatments for Alzheimer's disease.[7]
Education
edit edit sourceMacor trained as an organic chemist.[1] Macor received his B.S. in chemistry from the University of Notre Dame and his Ph.D. in chemistry from Princeton University in 1986, where he worked under Edward C. Taylor.[2][8]
Career
edit edit sourceMacor began his industrial career at Pfizer in 1986, where he was a co-inventor of eletriptan, a triptan marketed as Relpax for the acute treatment of migraine.[8][2] Eletriptan was approved by the FDA in 2002.[9]
He later joined Bristol-Myers Squibb in 1997, where he served as executive director of neuroscience chemistry.[8][1] At Bristol-Myers Squibb, he was a co-inventor in the program that produced the CGRP receptor antagonists rimegepant and zavegepant,[10][2][3][4] which were subsequently developed by Biohaven Pharmaceuticals and approved by the FDA in 2020 and 2023, respectively, for the treatment of migraine.[11][12]
He is also a co-inventor of sparsentan,[5][6] a dual endothelin and angiotensin II receptor antagonist developed by Travere Therapeutics and approved by the FDA in 2023 for the reduction of proteinuria in adults with IgA nephropathy.[13]
Macor’s work at Bristol-Myers Squibb also included the company’s Alzheimer’s disease program, where he contributed to the discovery of avagacestat (BMS-708163),[14] a γ-secretase inhibitor that advanced to Phase 2 clinical trials[15] before development was discontinued.[citation needed]
Macor is an author on more than 220 peer-reviewed publications and a named inventor on 150 issued U.S. patents.[citation needed]
Current clinical development
edit edit sourceActive clinical trials
edit edit source| Compound | Clinical development |
|---|---|
| Afimetoran | Phase 2 trials for systemic lupus erythematosus; active and not recruiting in the July 2026 sponsor record.[16] |
| CSTI-500 | A triple monoamine reuptake inhibitor in Phase 2a trials for Prader–Willi syndrome; first participant dosed in June 2026.[17] |
Programs between clinical stages
edit edit source| Compound | Clinical development |
|---|---|
| Pilavapadin | Phase 3 development planned following a January 2026 end-of-Phase 2 meeting for diabetic peripheral neuropathic pain.[18] |
| SION-451 | Phase 1 combination results reported in August 2026 for the cystic fibrosis program; next clinical development steps under evaluation.[19] |
Discontinued add-on program
edit edit source| Compound | Clinical development |
|---|---|
| SION-719 | Phase 2a trial for cystic fibrosis. In August 2026, the sponsor reported that the trial missed its key activity endpoint and that it would not advance SION-719 as an add-on to standard of care.[19] |
Honors
edit edit source- Robert M. Scarborough Award for Excellence in Medicinal Chemistry, ACS Division of Medicinal Chemistry (2009)[2]
- Inducted as an American Chemical Society Fellow (2011)[2]
- Alfred Burger Award in Medicinal Chemistry, American Chemical Society (2014)[2]
- Inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame (2014)[2]
- Edward E. Smissman Award in Medicinal Chemistry, ACS Division of Medicinal Chemistry (2019)[2]
- IUPAC–Richter Prize in Medicinal Chemistry (2020)[8]
Selected publications
edit edit source- Gillman, K. W.; et al. (2010). "Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor". ACS Medicinal Chemistry Letters. 1 (3): 120–124. doi:10.1021/ml1000239. PMC 4007960. PMID 24900185.
- Luo, G.; et al. (2012). "Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine". Journal of Medicinal Chemistry. 55 (23): 10644–10651. doi:10.1021/jm3013147. PMID 23153230.
References
edit edit source- ^ a b c Lisa M. Jarvis (2014-02-10). "Alfred Burger Award In Medicinal Chemistry". Chemical & Engineering News. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ a b c d e f g h i j "Dr. John Macor". American Chemical Society. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ a b "US8481546B2: CGRP receptor antagonist". United States Patent and Trademark Office, via Google Patents. 2013-07-09. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ a b "WO2022217008A1: Solid state forms of zavegepant and process for preparation thereof". World Intellectual Property Organization, via Google Patents. 2022-10-13. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ a b "US6638937B2: Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists". United States Patent and Trademark Office, via Google Patents. 2003-10-28. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ a b "WO2020132594A1: Amorphous sparsentan compositions". World Intellectual Property Organization, via Google Patents. 2020-06-25. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "Babylon Biosciences: Team". Babylon Biosciences. Retrieved 2026-09-10. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ a b c d "John Macor, PhD is Awarded the 2020 IUPAC-Richter Prize". Gedeon Richter. 2020-01-22. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "NDA 21-016: Relpax approval letter" (PDF). U.S. Food and Drug Administration. 2002-12-26. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ Carmen Drahl (2012-04-16). "BMS-927711 - Bristol-Myers Squibb". Chemical & Engineering News. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "Nurtec ODT: NDA 212728 approval package" (PDF). U.S. Food and Drug Administration. 2020-02-27. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "Drug Trials Snapshots: ZAVZPRET". U.S. Food and Drug Administration. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "Filspari: NDA 216403 approval package" (PDF). U.S. Food and Drug Administration. 2023-02-17. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable gamma-Secretase Inhibitor". Queen’s University Belfast research portal. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease". Archives of Neurology. 2012. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)". Bristol Myers Squibb. 2026-07-29. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome". ConSynance Therapeutics, via GlobeNewswire / CompuServe. 2026-06-16. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ "Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain". Lexicon Pharmaceuticals. 2026-01-21. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
- ^ a b "Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update". Sionna Therapeutics. 2026-08-10. Retrieved 2026-09-09. Wikipedia revision 1375923447, retrieved 2026-11-19
Text derived from https://en.wikipedia.org/w/index.php?oldid=1375923447 under CC BY-SA 4.0; modifications have been made.